Allegra Sales Decline Will Not Prompt OTC Switch, Aventis Says
This article was originally published in The Tan Sheet
Executive Summary
Decreasing Allegra sales in the face of increased competition from OTC antihistamines will not lead Aventis to pursue a switch for the drug, the firm stated during an Oct. 30 call on third-quarter results